About Cristina Cusin, MD

Dr. Cusin went to Medical School at the Universita degli Studi, in Milan, Italy, where she also completed a residency in Psychiatry.

Dr. Cusin was working as Psychiatrist in an inpatient unit and involved in research when in 2004 she decided to come to the U.S. for a Research Fellowship at Mass. General Hospital.

She decided to pursue further training in the U.S. and after completing the Adult Psychiatry Residency at MGH/McLean she joined the staff of the Depression Clinical & Research Program (DCRP), under the mentorship of Dr Maurizio Fava.

She is Assistant Professor in Psychiatry at Harvard Medical School

Dr. Cusin has an outpatient clinic at the DCRP and often performs consultations for patients with Treatment-Resistant Depression.She is one of the clinicians in the ECT team at MGH and she is the primary investigator involved in research studies on ketamine in treatment-resistant mood disorders at MGH. 

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Languages:

Locations

Depression Clinical and Research Program
One Bowdoin Square
6th Floor
Boston, MA 02114-2790
617-726-6421
Fax: 617-724-3028

Medical Education

  • MD, Universita Di Milano
  • Residency, Massachusetts General Hospital
  • Residency, Universita degli Studi di Milano
  • Fellowship, Universita Vita Salute San Raffaele

American Board Certifications

  • Psychiatry, American Board of Psychiatry and Neurology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Cusin's field of interest is Treatment Resistant Depression (TRD). 

At the Depression Clinical & Research Program (DCRP), she is involved in numerous clinical trials, sponsored by NIMH and foundations, investigating new pharmacologic treatments for Major Depression and TRD, including intravenous administration of ketamine and scopolamine

She is one of the programmers in the pivotal trial for Deep Brain Stimulation for MDD sponsored by Medtronic, for patients affected by extremely treatment-refractory depression.

Dr. Cusin is also developing two original projects aiming at detecting possible neurobiological mechanisms of placebo response in antidepressant clinical trials.

Publications